https://www.selleckchem.com/products/tpi-1.html
The current standard of care treatment for severe hemophilia A and B (SHA and SH is the prophylactic intravenous replacement of coagulation factor VIII or IX (FVIII/FIX) to prevent spontaneous bleeding. Persons with hemophilia without prophylactic treatment receive therapy in case of bleeding, i.e., on demand. To assess treatment patterns, utilization of products, and bleeding outcomes in a real-world cohort of persons with SHA and SHB, defined as FVIII or FIX activity less then 1%, data was retrospectively collected from hemophilia-spe
Like
Comment
Share
